May 2026
📣 VC round data is live. Check it out!
Largest BioTech Public Companies in Poland
Benchmark revenue and EBITDA valuation multiples for public comps like
Grupa Azoty, Celon Pharma, Selvita, Captor Therapeutics and Bioceltix.
 | Grupa Azoty SA is a holding company, which through its subsidiaries, produces and sells chemicals, plastics, fertilizers, titanium, and extracts sulfur products. The firm organizes itself into five segments based on the product type. The Agro fertilizer segment, which generates the majority of revenue, sells fertilizers and agrochemicals. The Plastics segment sells a variety of plastic products to the automotive, construction, food, and textile industries. The Energy segment produces and sells electricity. The Chemicals segment sells oxo alcohols and other chemicals and its other segment comprises activities such as laboratory services, property rental, and other activities. | $6 | +1% | $633M | $3B | 0.9x | 41.9x | ||
| Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder. | $6 | -10% | $303M | $317M | 6.5x | 76.9x | ||
| Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects. | $9 | +4% | $156M | $197M | 2.0x | 10.6x | ||
| Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options. | $21 | +126% | $131M | $127M | 29.1x | (14.0x) | ||
| Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis. | $23 | -17% | $130M | $113M | - | (28.6x) | ||
| Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways. | $4 | -50% | $101M | $100M | 4.3x | (4.5x) | ||
| Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland. | $1 | +2% | $97M | $112M | 1.4x | 7.9x | ||
| Synthaverse SA is a global pharmaceutical company. Its goal is to provide the best, innovative and unique solutions for medicine. Its work is based on scientific and health knowledge. Along with its expert approach, it allows the company to create reliable and unique products. It manufactures one of the few drugs used internationally in the oncological immunotherapy of bladder cancer. | $1 | -46% | $58M | $81M | 7.0x | (386.6x) | ||
| Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs. | $2 | +12% | $34M | $29M | - | (3.8x) | ||
| Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis. | $2 | -23% | $33M | $39M | 8.9x | (2.7x) | ||
| Nanogroup SA develops biotechnological and medical projects for diagnostics, therapy and rehabilitation of oncological patients. | $1 | -6% | $28M | $25M | 43158.5x | (17.5x) | ||
| Poltreg SA is a biotechnology company at the clinical stage developing an innovative generation of medicines using T-regulatory cells (TREGS) in the treatment of autoimmune diseases. | $5 | -40% | $28M | $27M | - | (8.2x) | ||
| Urteste SA specialises in the development of technology allowing the detection of cancers at the early stages of their development. The companies technology helps detect cancers by measuring the activity of the enzymes in urine. Urteste develops diagnostic tests for more than ten common cancers. | $12 | -15% | $18M | $17M | 2753.4x | (11.2x) | ||
| Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours. | $1 | +4% | $16M | $17M | 4.0x | 38.9x | ||
| Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions. | $5 | -22% | $13M | $17M | 0.5x | 4.6x | ||
| Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy. | $0 | +62% | $8M | $8M | 241.5x | (134.9x) | ||
| Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects. | $0 | -22% | $6M | $10M | - | (6.9x) | ||
| Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel. | $2 | -6% | $5M | $4M | 6.7x | (14.3x) | ||
| Hemp & Health SA is engaged in hemp and cannabis cultivation. The company processes harvested crops such as CBD and CBG, used for the production of white labels and private labels oils, creams, dried herbs and liquids for vaporization. | $0 | -25% | $4M | $4M | 70.3x | (11.4x) | ||
| Cannabis Poland SA is engaged in the business of cannabis, wherein it supplies plant products containing cannabinoids for pharmaceutical industry. | $0 | -32% | $3M | $3M | 44.8x | (4.3x) | ||
| Median | $2 | -12% | $31M | $28M | 6.9x | (5.7x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.